EUA review of Medigen vaccine pushed back to late July

The emergency use authorization (EUA) review of a COVID-19 vaccine candidate made by Taiwan-based Medigen Vaccine Biologics Corp. will likely be pushed back to late July due to missing documentation, Taiwan's Food and Drug Administration (FDA) said Monday.

(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)